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INTRODUCTION
In this issue Lenoir-Wijnkoop et al. (2014)
show that an affordable and widely avail-
able fermented dairy drink containing a
known and well-documented probiotic
could lead to health care system cost sav-
ings. This paper is just one in a sur-
prisingly large number of very recent
papers on probiotics, antibiotic-associated
diarrhea (AAD), and Clostridium difficile-
associated diarrhea (CDAD, recurrent-
CDAD, or CD infection: CDI). The revival
of attention for CDI is mainly caused
by the emergence of new hyper virulent
strains, a decrease of clinical response to
antibiotics, an increase of incidence and
prevalence and the existence of at least
three different toxins. Clostridium difficile
has a broad clinical manifestation from
asymptomatic (contagious) carriers, via
diarrhea toward pseudomembranous col-
itis, toxic megacolon, and death. Since
Clostridium difficile is a spore former it can
still cause endogenous self-contamination
even (or especially) after antibiotic treat-
ment. Furthermore, these spores are a con-
tamination hazard in health care facilities
and they heighten the transmission rates
(R-value). Taken together, all these factors
(reviewed in Hell et al., 2013) result in a
high unmet medical need with significant
socio-economic impact. Here, we would
like to put both the clinical and economic
impact of this paper in a broader “state of
the art” context, by adding alternative new
insights and references not yet available to
the Lenoir-Wijnkoop paper.
COST
The total cost of AAD, CDAD, and CDI
is dependent on the calculation method
used, as discussed at length in the Lenoir-
Wijnkoop paper, but is in the order of
several tens of billions of dollars annu-
ally. Direct cost of recurrent CDAD/CDI
ranges from 2000 (USA) to 3000 (UK)
euro per case/year with health care system
costs in the range of 4–6000 euro’s peak-
ing as high as 11,000 euro for recurrent-
CDI (reviewed in Hell et al., 2013). The
added, and real, cost to society is much
higher. Use of “double” doses probiotics
in Canada (where 1 in 10 CDI patients
succumbs to the disease) resulted in cost
savings of up to a 1000 euro per patient
(n = 1000 patients; Fansi et al., 2012).
RE-POOP-ULATIONWITH DONOR
FECES
Repoopulation, a term originally coined by
Petrof et al. (2013) based on their astonish-
ing results, pertains to the re-balancing of
an aberrant microbiota by infusing donor-
feces. In a very recent double blind placebo
controlled study (RCT), recurrent CDI
could be solved in over 80% of investi-
gated cases by duodenal infusion of donor-
feces, where vancomycin resolved disease
in 31% and vancomycin in combination
with bowel lavage in only 23%. These
results were so dramatic that the RCT was
stopped, after independent review in an
interim analysis, in order to provide feces
transplantation to the placebo group (Van
Nood et al., 2013). Feces transplantation
is under discussion with the FDA for pre-
sumed safety issues (but still allowed for
recurrent CDI) and remains a costly pro-
cedure. The high price and even a ban on
repoopulation has also led to (unwise and
unwanted) do it yourself repoopulation
instruction videos on the internet. Clearly,
reintroducing a complete new microbiota
is a long way from managing the same
problemwith a fermented dairy drink with
one to ten selected strains of lactic acid
bacteria.
UNMET MEDICAL NEED
AAD and CDAD are only two of several
forms of bowel irregularity introduced
by medical intervention. Other iatrogenic
bowel irregularities (IBI) are introduced
for instance by: enteral-nutrition-
deficiencies, hospital diet, colonoscopy-
damage/perforation, trauma, stress,
therapeutic irradiation, colectomy-asso-
ciated—pouchitis or—short-bowel-synd-
rome, surgery, chemotherapy, morphine
and other medicines, hospital infections,
and the length of time people are bedrid-
den (general lack of exercise). These
factors can deregulate normal gut motil-
ity and gut function. Moreover, they can
influence the living microbiota (1014 bac-
teria) of the gut. However, it should be
stressed that most of these IBI are usu-
ally mild and self-limiting, but in some
cases this can lead to persistent or recur-
rent obstipation or diarrhea, prolonged
hospital stay, serious complications, and
death (Hell et al., 2013). The incidence
of CDAD and CDI varies greatly from
center to center and has an enormous
impact on the outcome of the study. When
event rates are much lower than predicted,
the resulting low absolute risk reduction
might interfere with significance even in
large and overpowered studies (Daneman,
2013). So there is an enormous center-
to-center variation in CD-associated
problems and when incidence of CDAD
is lower than 1.2% probiotics might not
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be cost effective, as recently shown in a
meta-analysis based on all available data
(Daneman, 2013). However, recently it
was also shown that in a 240 bed hospi-
tal over the course of 22 months almost
two thousand patients were treated for
a (presumed) C. dif issue. Eventually,
only 15% (!) had lab confirmed positive
tests (unpublished, see Wickline, 2013).
Consequently, from premature babies
with NEC (necrotizing enterocolitis) via
healthy adults with weight (Mekkes et al.,
2013) or bowel problems, right through
to the elderly, bowel irregularities (in need
of bona fide diagnostics) cause signifi-
cant morbidity and mortality and form a
largely unmet medical need throughout
even a relatively “healthy” life (Islam et al.,
2012; Weenen et al., 2013a).
DIET, PROBIOTICS, AND PREBIOTICS
Prebiotics are non-digestible food ingre-
dients that stimulate the growth and/or
activity of bacteria in the digestive system
in ways claimed to be beneficial to health
(i.e., linked to stimulation of probiotics).
They were first identified and named by
Marcel Roberfroid in 1995 and are also
known as oligosaccharides or soluble-
fibers (not to be confused with food fiber).
Human milk oligosaccharides (HMOS)
represent the thirdmost abundant compo-
nent of human breast milk. More than a
hundred structurally distinct HMOS have
been identified. Recent studies have started
to link individual HMOS to infant health
and disease and suggest the importance
of a mother-infant match with regard to
HMOS composition (Marx et al., 2014).
Milk from domestic mammals has 10–100
fold less oligosaccharides than humanmilk
(Table 1). Oligosaccharides like galacto-
(GOS) and fructo-oligosaccharides (FOS,
including inulin) are routinely added to
most infant formulas and are also avail-
able in powdered form. It has long been
known that diets supplemented with GOS
and FOS have a prebiotic effect, encourag-
ing the growth of our “endogenous pro-
biotics” like bifidobacteria and reducing
opportunistic pathogens like Escherichia
coli, Bacteroides spp, and Clostridium spp.
Barrett (2013). Paradoxically, prebiotics
should not be added to probiotics during
GI transit because they cause a switch from
logarithmic to stationary growth phase
(Golowczyc et al., 2013) which lowers their
resistance to gastric acid (low pH) and
bile, by lowering the expression of stress
proteins (personal communication Dr. K.
Venema). On the other hand, metaboliz-
able sugars (like glucose) provide ATP via
glycolysis thereby enabling proton exclu-
sion potentially enhancing survival during
gastric transit (Corcoran et al., 2005). Next
to these indirect prebiotic effects in the
gut, GOS, and FOS also have direct effects,
such as pathogen-adhesion-inhibition to
the gut epithelium and modulating bind-
ing of selectins (Barrett, 2013; Roberts
et al., 2013). Consequently taking probi-
otics with small amounts of sugar helps
the strains to survive gastric and bile juices.
In the diet, the vegetables that contain rel-
atively large amounts of oligosaccharides
(like inulin) are, strangely enough, not
the ones we use when experiencing IBI
(iatrogenic bowel irregularities) like e.g.,
diarrhea. Furthermore, the first eight veg-
etables in the list are routinely found in
a Mediterranean diet. Hospital dieticians
and cooks could use the data of the Lenoir-
Wijnkoop study in conjunction with high
GOS and FOS foods for synergy (known
as synbiotics) and enhance the calculated
beneficial effects by minor dietary inter-
ventions at marginal extra cost.
FOOD-PHARMA CONVERGENCE AND
REGULATIONS
As we described recently, industries are
converging at the Food-Pharma inter-
face and work in different regulatory and
reimbursement areas on either functional
foods or medical foods (Weenen et al.,
2013b). Remarkably, although the core
technology domain is food within the
medical-food industry the technological
development is mainly driven by phar-
maceutical/pharmacological technologies.
When classified as functional foods, pro-
biotic effects pertaining to human health,
consist of claims subject to evaluation by
regulatory institutes such as the European
Food Safety Authority (EFSA) Panel on
Dietetic Products, Nutrition and Allergies
(NDA). As recently reviewed 78% of all
analyzed health claims are considered by
the NDA Panel as (possibly) beneficial
to human health, in particular the gut
health effects. However, in many cases,
the scientific substantiation of a particular
health claim, when analyzed in a Pharma
like manner, was deemed insufficient,
Table 1 | Prebiotics, (a.k.a. soluble fibers)
improving growth of probiotic bacteria, as
found in dietary components and milk ranked
by quantitative availability.
Recovered oligosaccharides as
% weight/weight fresh
Chicory/endive stalks 15–20
Garlic 9–16
Black salsify and leek 4–10
Onion and artichoke 2–6
Asparagus 2–3
Wheat 1–4
Oats (and human breast milk) 0.5–1.5
Banana 0.3–0.7
Domestic-placental-mammal milk 0.01–0.1
and most applications were turned down
(Binnendijk and Rijkers, 2013). Currently,
there is a vivid debate as to whether
functional foods should be indeed regu-
lated more stringently as medical foods (as
EFSA is now doing), the largely EU-policy-
driven outcome is eagerly awaited by sci-
entists, clinicians and industry alike (Hill
and Sanders, 2013). For near-future health
claim applications concerning probiotics
to be successful, they should include pre-
cise dose and strain specifications, specific
statements on what exactly the microor-
ganism affects, and overpowered intent
to treat (ITT) analysis of the clinical
trials in the targeted (general) popula-
tion. An excellent and recent example
of how such study should be performed
along those very stringent guidelines, con-
vincingly showing a dose-dependent 50%
reduction of AADwith a probioticmixture
was published by Ouwehand et al. (2014).
SAFETY
Recently we systematically studied adverse
events as related to probiotics, in all
placebo controlled RCT’s those AEs found
were considered unrelated to the study
product (which was also well-tolerated),
and there were no major safety concerns in
either verum or placebo. However, incon-
sistent, imprecise, and potentially incom-
plete reporting as well as the variation in
probiotic strains, dosages, administration
regimes, study populations and reported
outcomes, greatly limits the generalizabil-
ity of conclusions and argues convincingly
for obligatory, and standardized behavior
on adverse events (CTCAE) reporting in
“food” studies (Van den Nieuwboer et al.,
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2014). The safety, quality, and quantity
(CFU), specifically in relation to antibi-
otic sensitivity, of medicinal products con-
taining probiotics also needs to be estab-
lished as recently and satisfactorily done
for Polish products (Wiatrzyk et al., 2013).
DOSE AND PRODUCT CHOICE
Without going into too much detail it is
clear from literature that probiotics work
in a dose-dependent manner with effec-
tiveness for AAD or CDAD at or around
10–17 billion bacteria per day (e.g., dou-
ble dose in Lenoir-Wijnkoop study and
Ouwehand et al., 2014). Most products
on the market do not contain those high
numbers. However, the dosing is strain-
dependent and dose-response relations
need to be established for each different
strain/product or cocktail/combination
(Hell et al., 2013). Moreover, recently
Douillard et al. (2013) showed that the
draft genomes of two competing brands of
dairy drink based probiotic products are
close to identical to each other and dif-
fer by no more than minor chromosomal
re-arrangements, substitutions, insertions,
and deletions, as evident from the ver-
ified presence of one insertion-deletion
(InDel) and only 29 single-nucleotide
polymorphisms (SNPs). Their observa-
tions could imply that results obtained
in human experiments performed with
the Actimel® (as used in the Lenoir-
Wijnkoop study) and Yakult® strains can
be compared with each other as these
strains share a recent common ancestor.
Nevertheless, as the human intervention
trials are not conducted on the strains
only but mainly on the final food form
(matrix/sugar/additives), in accordance
with the current regulation, and there-
fore differences in matrix, the bacterial
composition and metabolites can lead
to significant differences in outcomes.
Similar relations could exist for other,
competing products in the market and
accentuate the EFSA call for full genome
sequencing identification data and clear
and detailed description of matrix and
formulation. Finally, dose and product
choice also has an impact when com-
paring single- and multi species/strain
products. As recently shown in the
Allen study (cfr Daneman, 2013) not all
strain/species/dose combinations will per-
form effectively. However, this and other
negative studies have barely any impact on
the meta-analysis outcome of the accepted
effectiveness of (working) probiotics in
AAD (Cochrane review by Goldenberg
et al., 2013). Furthermore, such negative
studies are less convincing when only low
incidence (and consequently low abso-
lute risk reduction) of CDAD or AAD are
found in the control group (Daneman,
2013).
CONCLUSIONS
As described in the Lenoir-Wijnkoop
paper in this issue a new and effective gen-
eration of probiotic products, in which all
aspects of health, disease, and pathogen-
exclusion are incorporated, is emerging
(cfr also: Hell et al., 2013; Ouwehand et al.,
2014). When given orally and in the right
dose in combination with exercise and an
appropriate diet, probiotics can give a clear
healthcare system cost reduction for sev-
eral forms of IBI with notable examples
like AAD, CDAD, and CDI. Probiotics are
safe and reduce disease/antibiotic-related
adverse events by at least 20%. Treatment
dose and protocols are product- and
strain-dependent. Studies combining bio-
logical, clinical, and economic data help
predict whether the benefits of a protocol
or policy (e.g., probiotics and diet) out-
weigh its costs. Perfect evaluation of all
present and future costs and benefits is
challenging, but ranking of best alterna-
tives should result in economic efficiency
and social welfare in vulnerable patient
groups.
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